ArticleFrontiers in endocrinology2025
SWE, C-TIRADS and AI-assisted diagnostic systems in distinguishing thyroid nodules of different lesion size: Which has better diagnostic performance?
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the diagnostic performance of shear wave elastography (SWE), Chinese Thyroid Imaging Reporting and Data System (C-TIRADS), and an artificial intelligence (AI)-assisted diagnostic system in differentiating thyroid nodules of different sizes. Methods: A total of 103 thyroid nodules in 90 patients were prospectively analyzed and divided into two groups based on the maximum diameter: <10 mm and ≥10 mm. Each thyroid nodule was evaluated using three methods: conventional ultrasound for C-TIRADS scoring, shear wave elastography (SWE), and AI-assisted diagnosis. The diagnostic performance of individual methods and their combinations was assessed within each nodule size group using sensitivity, specificity, and area under the receiver operating characteristic (ROC) curve. For combined assessments, a nodule was considered positive if any constituent method indicated malignancy. Intergroup comparisons of AUC values were performed using DeLong's test to evaluate the effect of nodule size on diagnostic performance. Results: In nodules ≥1 cm, AI demonstrated excellent performance (AUC = 0.875, sensitivity = 96.43%, specificity = 77.78%), and C-TIRADS also performed well (AUC = 0.834, sensitivity = 96.55%, specificity = 70.37%). Among SWE parameters, Emax achieved the highest AUC (0.895). The diagnostic efficacy of AI combined with C-TIRADS (AUC = 0.852) was comparable to that of AI + C-TIRADS + Emax. In subcentimeter nodules, diagnostic performance decreased, with AI achieving an AUC of 0.654 and C-TIRADS an AUC of 0.524, whereas Emean retained moderate discriminative ability (AUC = 0.821). Conclusion: AI combined with C-TIRADS provides an efficient and practical strategy for diagnosing thyroid nodules ≥1 cm. For subcentimeter nodules, Emean retains discriminative ability, indicating potential clinical value in assessment of small lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.